Clinical trial · no report yet · Phase 3
FREEDOM2
An Efficacy and Safety Study of Fedratinib Compared to Best Available Therapy in Subjects With DIPSS-intermediate or High-risk Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, or Post-essential Thrombocythemia Myelofibrosis and Previously Treated With Ruxolitinib
- NCT03952039 ↗
- Completed
- Celgene
- 39 commentary sources found
- Standard
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Commentary we found
Podcasts, YouTube videos and X posts in our index that name this trial. A report screens them, searches for more and cites what clinicians said when it is built.
| Channel | Found | |
|---|---|---|
| YouTube | 23 | |
| Podcasts | 13 | |
| X threads | 3 |
The trial
ClinicalTrials.gov- Official title
- A Phase 3, Multicenter, Open-label, Randomized Study to Evaluate the Efficacy and Safety of Fedratinib Compared to Best Available Therapy (BAT) in Subjects With DIPSS (Dynamic International Prognostic Scoring System)-Intermediate or High-risk Primary Myelofibrosis (PMF), Post-polycythemia Vera Myelofibrosis (Post-PV MF), or Post-essential Thrombocythemia Myelofibrosis (Post-ET MF) and Previously Treated With Ruxolitinib
- Phase
- Phase 3
- Status
- Completed
- Conditions
- Primary Myelofibrosis; Post-Polycythemia Vera; Myelofibrosis
- Interventions
- FEDRATINIB; Best Available Therapy (BAT)
- Arms
- Fedratinib 400mg/day · Experimental
- Best Available Therapy (BAT) · Active comparator
- Enrollment
- 202
- Primary outcomes
- Spleen Volume Response Rate (RR)
- Sponsor
- Celgene with Impact Biomedicines, Inc., a wholly owned subsidiary of Celgene Corporation
- Start
- Sep 9, 2019
- Primary completion
- Dec 15, 2022
- Results posted
- Yes
- Registry record
- NCT03952039 · updated Aug 28, 2025
Publications
linked from the registry- Harrison CN, Mesa R, Talpaz M, Al-Ali HK, Xicoy B, Passamonti F, Palandri F, Benevolo G, Vannucchi AM, Mediavilla C, Iurlo A, Kim I, Rose S, Brown P, Hernandez C, Wang J, Kiladjian JJ. Efficacy and safety of fedratinib in patients with myelofibrosis previously treated with ruxolitinib (FREEDOM2): results from a multicentre, open-label, randomised, controlled, phase 3 trial. Lancet Haematol. 2024 Oct;11(10):e729-e740. doi: 10.1016/S2352-3026(24)00212-6. Epub 2024 Sep 9. PubMed 39265613